Dr Reddys Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

At the conclusion of the inspection, USFDA issued a Form-483 with seven observations. The company said it will address within the stipulated timeline.

Previously, the USFDA had conducted a Pre-Approval Inspection (PAI) at the same Hyderabad facility between 4 September and 12 September 2025, following which it had issued five observations.

Hyderabad-based Dr. Reddy?s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company reported a 86.14% decline in consolidated net profit to Rs 220.9 crore on 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 over Q4 FY25.

The counter advanced 1.63% to settle at Rs 1,350 on Thursday, 25th June 2026. The NSE and BSE remain closed today on account of Muharram.

Powered by Capital Market - Live News

Dr Reddys Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1350.6, up 1.67% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.71% on the day, quoting at 24192.85. The Sensex is at 77548.16, up 0.72%. Dr Reddys Laboratories Ltd has added around 1.71% in last one month.

Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has added around 1.66% in last one month and is currently quoting at 25018.95, up 0.2% on the day. The volume in the stock stood at 10.78 lakh shares today, compared to the daily average of 15.46 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1353.9, up 2.07% on the day. Dr Reddys Laboratories Ltd is up 2.2% in last one year as compared to a 5.31% fall in NIFTY and a 14.95% fall in the Nifty Pharma index.

The PE of the stock is 34.44 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 22 July 2026.

Dr Reddys Laboratories has allotted 6,730 equity shares under ESOP on 19 June 2026. Post allotment, the paid up equity share capital has increased to 83,46,76,800 equity shares of Re 1 each.